Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin1,2 With Onswik, Lilly's type 2 diabetes portfolio expands to include a once-weekly basal insulin, alongside existing treatment options across insulins, incretins, oral and injectable medications...